BVF PARTNERS L P/IL Insider Trading Transactions
Get free email notifications about insider trading for BVF PARTNERS L P/IL.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of BVF PARTNERS L P/IL. BVF PARTNERS L P/IL is in KENT INTERNATIONAL HOLDINGS INC ($CRTQ) and 10% Owner in LIGAND PHARMACEUTICALS INC ($LGND) and 10% Owner in Capstone Therapeutics Corp. ($CAPS) and 10% Owner in REPLIGEN CORP ($RGEN) and 10% Owner in AVIGEN INC \DE ($AVGN) and 10% Owner in NEUROCRINE BIOSCIENCES INC ($NBIX) and 10% Owner in Astex Pharmaceuticals, Inc ($SUPG) and 10% Owner in ARQULE INC ($ARQL) and 10% Owner in NEUROBIOLOGICAL TECHNOLOGIES INC /CA/ ($NTII) and 10% Owner in RIGEL PHARMACEUTICALS INC ($RIGL) and 10% Owner in ARRAY BIOPHARMA INC ($ARRY) and 10% Owner in DYNAVAX TECHNOLOGIES CORP ($DVAX) and 10% Owner in EPIRUS Biopharmaceuticals, Inc. ($CRXX) and 10% Owner in CATALYST BIOSCIENCES, INC. ($CBIO) and 10% Owner in ICAGEN INC ($ICGN) and 10% Owner in ChemoCentryx, Inc. ($CCXI) and 10% Owner in Celera CORP ($CRA) and 10% Owner in ABBOTT BIOTHERAPEUTICS CORP ($FACT).
Latest Insider Trading Transactions of BVF PARTNERS L P/IL
Sentiment: All, FACT, ARQL, ARRY, SUPG, AVGN, CAPS, CBIO, CRA, CCXI, DVAX, CRXX, ICGN, CRTQ, LGND, NTII, NBIX, RGEN, RIGL
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jul 05 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.25 | 700 | 175 | 828,000 | 827.3 K to 828 K (+0.08 %) |
Jul 05 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.25 | 1,150 | 287 | 1,230,038 | 1.2 M to 1.2 M (+0.09 %) |
May 17 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.03 | 92,000 | 738,760 | 19,127,967 | 19 M to 19.1 M (+0.48 %) |
May 17 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.03 | 24,000 | 192,720 | 19,035,967 | 19 M to 19 M (+0.13 %) |
May 17 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.03 | 35,300 | 283,459 | 19,011,967 | 19 M to 19 M (+0.19 %) |
May 17 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.03 | 80,600 | 647,218 | 18,976,667 | 18.9 M to 19 M (+0.43 %) |
May 17 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.03 | 19,900 | 159,797 | 18,896,067 | 18.9 M to 18.9 M (+0.11 %) |
May 17 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.03 | 30,150 | 242,105 | 18,876,167 | 18.8 M to 18.9 M (+0.16 %) |
May 17 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.03 | 6,600 | 52,998 | 18,846,017 | 18.8 M to 18.8 M (+0.04 %) |
May 17 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.03 | 650 | 5,220 | 18,839,417 | 18.8 M to 18.8 M (0.00 %) |
May 17 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.03 | 1,550 | 12,447 | 18,838,767 | 18.8 M to 18.8 M (+0.01 %) |
May 10 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.05 | 207,000 | 1,665,750 | 15,760,417 | 15.6 M to 15.8 M (+1.33 %) |
May 10 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.05 | 60,000 | 482,826 | 15,553,417 | 15.5 M to 15.6 M (+0.39 %) |
May 10 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.05 | 87,000 | 700,098 | 15,493,417 | 15.4 M to 15.5 M (+0.56 %) |
May 10 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.05 | 655,000 | 5,270,523 | 15,406,417 | 14.8 M to 15.4 M (+4.44 %) |
May 10 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.05 | 189,000 | 1,520,807 | 14,751,417 | 14.6 M to 14.8 M (+1.30 %) |
May 10 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.05 | 273,200 | 2,198,331 | 14,562,417 | 14.3 M to 14.6 M (+1.91 %) |
May 10 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.05 | 61,000 | 491,050 | 14,289,217 | 14.2 M to 14.3 M (+0.43 %) |
May 10 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.05 | 18,000 | 144,900 | 14,228,217 | 14.2 M to 14.2 M (+0.13 %) |
May 10 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.05 | 25,000 | 201,250 | 14,210,217 | 14.2 M to 14.2 M (+0.18 %) |
May 12 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.03 | 112,000 | 899,326 | 18,837,217 | 18.7 M to 18.8 M (+0.60 %) |
May 12 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.03 | 32,000 | 256,950 | 18,725,217 | 18.7 M to 18.7 M (+0.17 %) |
May 12 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.03 | 46,400 | 372,578 | 18,693,217 | 18.6 M to 18.7 M (+0.25 %) |
May 12 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.03 | 1,491,400 | 11,974,600 | 18,646,817 | 17.2 M to 18.6 M (+8.69 %) |
May 12 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.03 | 387,700 | 3,112,882 | 17,155,417 | 16.8 M to 17.2 M (+2.31 %) |
May 12 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.03 | 575,900 | 4,623,959 | 16,767,717 | 16.2 M to 16.8 M (+3.56 %) |
May 12 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.05 | 353,100 | 2,841,325 | 16,191,817 | 15.8 M to 16.2 M (+2.23 %) |
May 12 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.05 | 19,250 | 154,901 | 15,838,717 | 15.8 M to 15.8 M (+0.12 %) |
May 12 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.05 | 59,050 | 475,164 | 15,819,467 | 15.8 M to 15.8 M (+0.37 %) |
May 06 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.05 | 259,000 | 2,083,992 | 14,185,217 | 13.9 M to 14.2 M (+1.86 %) |
May 06 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.05 | 75,000 | 603,473 | 13,926,217 | 13.9 M to 13.9 M (+0.54 %) |
May 06 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.05 | 107,400 | 864,173 | 13,851,217 | 13.7 M to 13.9 M (+0.78 %) |
May 06 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.05 | 1,313,000 | 10,569,519 | 13,743,817 | 12.4 M to 13.7 M (+10.56 %) |
May 06 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.05 | 379,000 | 3,050,912 | 12,430,817 | 12.1 M to 12.4 M (+3.14 %) |
May 06 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.05 | 548,000 | 4,411,345 | 12,051,817 | 11.5 M to 12.1 M (+4.76 %) |
Apr 22 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 7.99 | 539,500 | 4,313,195 | 11,493,817 | 11 M to 11.5 M (+4.92 %) |
Apr 22 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 7.99 | 140,200 | 1,120,871 | 10,954,317 | 10.8 M to 11 M (+1.30 %) |
Apr 22 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 7.99 | 208,400 | 1,666,116 | 10,814,117 | 10.6 M to 10.8 M (+1.96 %) |
Apr 22 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.05 | 56,800 | 457,223 | 10,605,717 | 10.5 M to 10.6 M (+0.54 %) |
Apr 22 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.05 | 14,800 | 119,136 | 10,548,917 | 10.5 M to 10.5 M (+0.14 %) |
Apr 22 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.05 | 21,900 | 176,288 | 10,534,117 | 10.5 M to 10.5 M (+0.21 %) |
Apr 19 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.07 | 60,600 | 489,042 | 10,512,217 | 10.5 M to 10.5 M (+0.58 %) |
Apr 19 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.07 | 12,500 | 100,875 | 10,451,617 | 10.4 M to 10.5 M (+0.12 %) |
Apr 19 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.07 | 19,100 | 154,137 | 10,439,117 | 10.4 M to 10.4 M (+0.18 %) |
Apr 19 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.08 | 55,000 | 444,224 | 10,420,017 | 10.4 M to 10.4 M (+0.53 %) |
Apr 19 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.08 | 16,000 | 129,229 | 10,365,017 | 10.3 M to 10.4 M (+0.15 %) |
Apr 19 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.08 | 23,000 | 185,766 | 10,349,017 | 10.3 M to 10.3 M (+0.22 %) |
Apr 14 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.05 | 42,000 | 337,911 | 10,326,017 | 10.3 M to 10.3 M (+0.41 %) |
Apr 14 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.05 | 12,000 | 96,546 | 10,284,017 | 10.3 M to 10.3 M (+0.12 %) |
Apr 14 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.05 | 18,100 | 145,624 | 10,272,017 | 10.3 M to 10.3 M (+0.18 %) |
Apr 14 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.07 | 56,000 | 451,954 | 10,253,917 | 10.2 M to 10.3 M (+0.55 %) |
Apr 14 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.07 | 15,000 | 121,059 | 10,197,917 | 10.2 M to 10.2 M (+0.15 %) |
Apr 14 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.07 | 22,300 | 179,974 | 10,182,917 | 10.2 M to 10.2 M (+0.22 %) |
Apr 14 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.03 | 30,000 | 240,900 | 10,160,617 | 10.1 M to 10.2 M (+0.30 %) |
Apr 14 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.03 | 7,900 | 63,437 | 10,130,617 | 10.1 M to 10.1 M (+0.08 %) |
Apr 14 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.03 | 11,700 | 93,951 | 10,122,717 | 10.1 M to 10.1 M (+0.12 %) |
Apr 11 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.07 | 90,000 | 726,039 | 10,111,017 | 10 M to 10.1 M (+0.90 %) |
Apr 11 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.07 | 15,500 | 125,040 | 10,021,017 | 10 M to 10 M (+0.15 %) |
Apr 11 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.07 | 34,200 | 275,895 | 10,005,517 | 10 M to 10 M (+0.34 %) |
Apr 11 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.14 | 35,715 | 290,606 | 9,971,317 | 9.9 M to 10 M (+0.36 %) |
Apr 11 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.14 | 10,310 | 83,890 | 9,935,602 | 9.9 M to 9.9 M (+0.10 %) |
Apr 11 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.17 | 410,000 | 3,351,299 | 9,925,292 | 9.5 M to 9.9 M (+4.31 %) |
Apr 11 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.17 | 44,900 | 367,008 | 9,515,292 | 9.5 M to 9.5 M (+0.47 %) |
Apr 07 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.22 | 125,000 | 1,027,263 | 9,470,392 | 9.3 M to 9.5 M (+1.34 %) |
Apr 07 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.18 | 33,000 | 270,079 | 9,345,392 | 9.3 M to 9.3 M (+0.35 %) |
Apr 07 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.18 | 10,000 | 81,842 | 9,312,392 | 9.3 M to 9.3 M (+0.11 %) |
Apr 07 2011 | CRA | Celera CORP | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 8.18 | 14,000 | 114,579 | 9,302,392 | 9.3 M to 9.3 M (+0.15 %) |
Jun 29 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.25 | 7,100 | 1,763 | 3,180,750 | 3.2 M to 3.2 M (+0.22 %) |
Jun 29 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.25 | 18,450 | 4,613 | 3,173,650 | 3.2 M to 3.2 M (+0.58 %) |
Jun 29 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.25 | 40,200 | 10,050 | 3,155,200 | 3.1 M to 3.2 M (+1.29 %) |
Jun 29 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.25 | 2,400 | 596 | 827,300 | 824.9 K to 827.3 K (+0.29 %) |
Jun 29 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.25 | 4,800 | 1,200 | 824,900 | 820.1 K to 824.9 K (+0.59 %) |
Jun 29 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.25 | 1,700 | 425 | 820,100 | 818.4 K to 820.1 K (+0.21 %) |
Jun 29 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.25 | 3,450 | 857 | 1,228,888 | 1.2 M to 1.2 M (+0.28 %) |
Jun 29 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.25 | 7,150 | 1,788 | 1,225,438 | 1.2 M to 1.2 M (+0.59 %) |
Jun 29 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.25 | 14,800 | 3,700 | 1,218,288 | 1.2 M to 1.2 M (+1.23 %) |
Apr 21 2010 | SUPG | Astex Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 3.54 | 61,000 | 216,025 | 5,583,399 | 5.6 M to 5.6 M (-1.08 %) |
Apr 21 2010 | SUPG | Astex Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 3.54 | 18,000 | 63,745 | 5,644,399 | 5.7 M to 5.6 M (-0.32 %) |
Apr 21 2010 | SUPG | Astex Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 3.54 | 25,000 | 88,535 | 5,662,399 | 5.7 M to 5.7 M (-0.44 %) |
Apr 21 2010 | SUPG | Astex Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 3.58 | 39,000 | 139,484 | 5,687,399 | 5.7 M to 5.7 M (-0.68 %) |
Apr 21 2010 | SUPG | Astex Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 3.58 | 11,000 | 39,342 | 5,726,399 | 5.7 M to 5.7 M (-0.19 %) |
Apr 21 2010 | SUPG | Astex Pharmaceutic ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 3.58 | 16,000 | 57,224 | 5,737,399 | 5.8 M to 5.7 M (-0.28 %) |
Apr 13 2010 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.80 | 61,000 | 170,916 | 5,041,447 | 5.1 M to 5 M (-1.20 %) |
Apr 13 2010 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.80 | 18,000 | 50,434 | 5,102,447 | 5.1 M to 5.1 M (-0.35 %) |
Apr 13 2010 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.80 | 25,000 | 70,048 | 5,120,447 | 5.1 M to 5.1 M (-0.49 %) |
Apr 13 2010 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.76 | 55,000 | 151,712 | 5,145,447 | 5.2 M to 5.1 M (-1.06 %) |
Apr 13 2010 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.76 | 16,000 | 44,134 | 5,200,447 | 5.2 M to 5.2 M (-0.31 %) |
Apr 13 2010 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.76 | 23,000 | 63,443 | 5,216,447 | 5.2 M to 5.2 M (-0.44 %) |
Apr 01 2010 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.70 | 1,000 | 2,700 | 5,239,447 | 5.2 M to 5.2 M (-0.02 %) |
Apr 01 2010 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.70 | 61,000 | 164,731 | 5,240,447 | 5.3 M to 5.2 M (-1.15 %) |
Apr 01 2010 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.70 | 18,000 | 48,609 | 5,301,447 | 5.3 M to 5.3 M (-0.34 %) |
Apr 01 2010 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.70 | 25,000 | 67,513 | 5,319,447 | 5.3 M to 5.3 M (-0.47 %) |
Apr 07 2010 | ARQL | ARQULE INC | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 6.13 | 354,000 | 2,170,303 | 4,208,073 | 4.6 M to 4.2 M (-7.76 %) |
Apr 07 2010 | ARQL | ARQULE INC | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 6.13 | 102,000 | 625,342 | 4,562,073 | 4.7 M to 4.6 M (-2.19 %) |
Apr 07 2010 | ARQL | ARQULE INC | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 6.13 | 147,000 | 901,228 | 4,664,073 | 4.8 M to 4.7 M (-3.06 %) |
Mar 29 2010 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.70 | 45,000 | 121,604 | 5,344,447 | 5.4 M to 5.3 M (-0.83 %) |
Mar 29 2010 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.70 | 13,000 | 35,130 | 5,389,447 | 5.4 M to 5.4 M (-0.24 %) |
Mar 29 2010 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.70 | 19,100 | 51,614 | 5,402,447 | 5.4 M to 5.4 M (-0.35 %) |
Mar 29 2010 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.70 | 18,000 | 48,605 | 5,421,547 | 5.4 M to 5.4 M (-0.33 %) |
Mar 29 2010 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.70 | 5,000 | 13,502 | 5,439,547 | 5.4 M to 5.4 M (-0.09 %) |
Mar 29 2010 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.70 | 8,200 | 22,142 | 5,444,547 | 5.5 M to 5.4 M (-0.15 %) |
Mar 29 2010 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.70 | 179,000 | 483,300 | 5,452,747 | 5.6 M to 5.5 M (-3.18 %) |
Mar 29 2010 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.70 | 52,000 | 140,400 | 5,631,747 | 5.7 M to 5.6 M (-0.91 %) |
Mar 29 2010 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.70 | 73,800 | 199,260 | 5,683,747 | 5.8 M to 5.7 M (-1.28 %) |
Mar 24 2010 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.75 | 51,000 | 140,444 | 5,757,547 | 5.8 M to 5.8 M (-0.88 %) |
Mar 24 2010 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.75 | 15,000 | 41,307 | 5,808,547 | 5.8 M to 5.8 M (-0.26 %) |
Mar 24 2010 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.75 | 22,000 | 60,584 | 5,823,547 | 5.8 M to 5.8 M (-0.38 %) |
Mar 24 2010 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.75 | 17,000 | 46,750 | 5,845,547 | 5.9 M to 5.8 M (-0.29 %) |
Mar 24 2010 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.75 | 5,000 | 13,750 | 5,862,547 | 5.9 M to 5.9 M (-0.09 %) |
Mar 24 2010 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.75 | 7,000 | 19,250 | 5,867,547 | 5.9 M to 5.9 M (-0.12 %) |
Mar 24 2010 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.77 | 42,000 | 116,315 | 5,874,547 | 5.9 M to 5.9 M (-0.71 %) |
Mar 24 2010 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.77 | 12,000 | 33,233 | 5,916,547 | 5.9 M to 5.9 M (-0.20 %) |
Mar 24 2010 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.77 | 18,000 | 49,849 | 5,928,547 | 5.9 M to 5.9 M (-0.30 %) |
Feb 09 2010 | FACT | ABBOTT BIOTHERAPEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.69 | 11,000 | 172,563 | 3,940,070 | 3.9 M to 3.9 M (+0.28 %) |
Feb 09 2010 | FACT | ABBOTT BIOTHERAPEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.69 | 3,000 | 47,063 | 3,929,070 | 3.9 M to 3.9 M (+0.08 %) |
Feb 09 2010 | FACT | ABBOTT BIOTHERAPEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.69 | 5,000 | 78,438 | 3,926,070 | 3.9 M to 3.9 M (+0.13 %) |
Feb 09 2010 | FACT | ABBOTT BIOTHERAPEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.37 | 9,000 | 138,290 | 3,921,070 | 3.9 M to 3.9 M (+0.23 %) |
Feb 09 2010 | FACT | ABBOTT BIOTHERAPEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.37 | 3,000 | 46,100 | 3,912,070 | 3.9 M to 3.9 M (+0.08 %) |
Feb 09 2010 | FACT | ABBOTT BIOTHERAPEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.37 | 3,200 | 49,173 | 3,909,070 | 3.9 M to 3.9 M (+0.08 %) |
Feb 09 2010 | FACT | ABBOTT BIOTHERAPEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.00 | 3,000 | 45,000 | 3,905,870 | 3.9 M to 3.9 M (+0.08 %) |
Feb 09 2010 | FACT | ABBOTT BIOTHERAPEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.00 | 1,000 | 15,000 | 3,902,870 | 3.9 M to 3.9 M (+0.03 %) |
Feb 09 2010 | FACT | ABBOTT BIOTHERAPEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.00 | 1,000 | 15,000 | 3,901,870 | 3.9 M to 3.9 M (+0.03 %) |
Feb 04 2010 | FACT | ABBOTT BIOTHERAPEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.63 | 73,000 | 1,141,121 | 3,900,870 | 3.8 M to 3.9 M (+1.91 %) |
Feb 04 2010 | FACT | ABBOTT BIOTHERAPEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.63 | 21,000 | 328,268 | 3,827,870 | 3.8 M to 3.8 M (+0.55 %) |
Feb 04 2010 | FACT | ABBOTT BIOTHERAPEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.63 | 29,611 | 462,873 | 3,806,870 | 3.8 M to 3.8 M (+0.78 %) |
Feb 04 2010 | FACT | ABBOTT BIOTHERAPEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.80 | 7,000 | 110,600 | 3,777,259 | 3.8 M to 3.8 M (+0.19 %) |
Feb 04 2010 | FACT | ABBOTT BIOTHERAPEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.80 | 2,000 | 31,600 | 3,770,259 | 3.8 M to 3.8 M (+0.05 %) |
Feb 04 2010 | FACT | ABBOTT BIOTHERAPEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.80 | 3,138 | 49,580 | 3,768,259 | 3.8 M to 3.8 M (+0.08 %) |
Feb 04 2010 | FACT | ABBOTT BIOTHERAPEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.80 | 12,000 | 189,600 | 3,765,121 | 3.8 M to 3.8 M (+0.32 %) |
Feb 04 2010 | FACT | ABBOTT BIOTHERAPEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.80 | 4,000 | 63,200 | 3,753,121 | 3.7 M to 3.8 M (+0.11 %) |
Feb 04 2010 | FACT | ABBOTT BIOTHERAPEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.80 | 5,000 | 79,000 | 3,749,121 | 3.7 M to 3.7 M (+0.13 %) |
Jan 29 2010 | FACT | ABBOTT BIOTHERAPEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.72 | 60,000 | 943,140 | 3,744,121 | 3.7 M to 3.7 M (+1.63 %) |
Jan 29 2010 | FACT | ABBOTT BIOTHERAPEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.72 | 17,000 | 267,223 | 3,684,121 | 3.7 M to 3.7 M (+0.46 %) |
Jan 29 2010 | FACT | ABBOTT BIOTHERAPEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.72 | 25,000 | 392,975 | 3,667,121 | 3.6 M to 3.7 M (+0.69 %) |
Jan 29 2010 | FACT | ABBOTT BIOTHERAPEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.70 | 30,000 | 471,111 | 3,642,121 | 3.6 M to 3.6 M (+0.83 %) |
Jan 29 2010 | FACT | ABBOTT BIOTHERAPEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.70 | 9,000 | 141,333 | 3,612,121 | 3.6 M to 3.6 M (+0.25 %) |
Jan 29 2010 | FACT | ABBOTT BIOTHERAPEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.70 | 12,600 | 197,867 | 3,603,121 | 3.6 M to 3.6 M (+0.35 %) |
Jan 29 2010 | FACT | ABBOTT BIOTHERAPEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.66 | 69,000 | 1,080,775 | 3,590,521 | 3.5 M to 3.6 M (+1.96 %) |
Jan 29 2010 | FACT | ABBOTT BIOTHERAPEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.66 | 20,000 | 313,268 | 3,521,521 | 3.5 M to 3.5 M (+0.57 %) |
Jan 29 2010 | FACT | ABBOTT BIOTHERAPEU ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.66 | 29,000 | 454,239 | 3,501,521 | 3.5 M to 3.5 M (+0.84 %) |
Oct 20 2009 | CBIO | CATALYST BIOSCIENC ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 23.60 | 374,000 | 8,824,567 | 2,061,925 | 2.4 M to 2.1 M (-15.35 %) |
Oct 20 2009 | CBIO | CATALYST BIOSCIENC ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 23.60 | 108,000 | 2,548,271 | 2,435,925 | 2.5 M to 2.4 M (-4.25 %) |
Oct 20 2009 | CBIO | CATALYST BIOSCIENC ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 23.60 | 156,400 | 3,690,274 | 2,543,925 | 2.7 M to 2.5 M (-5.79 %) |
Oct 23 2009 | NTII | NEUROBIOLOGICAL TE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 0.91 | 2,692,493 | 2,450,169 | 331,998 | 3 M to 332 K (-89.02 %) |
Oct 23 2009 | NTII | NEUROBIOLOGICAL TE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 0.91 | 777,408 | 707,441 | 3,024,491 | 3.8 M to 3 M (-20.45 %) |
Oct 23 2009 | NTII | NEUROBIOLOGICAL TE ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 0.91 | 1,136,494 | 1,034,210 | 3,801,899 | 4.9 M to 3.8 M (-23.01 %) |
Dec 24 2009 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 0.80 | 1,863,000 | 1,490,400 | 6,830,972 | 8.7 M to 6.8 M (-21.43 %) |
Dec 24 2009 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 0.80 | 538,000 | 430,400 | 8,693,972 | 9.2 M to 8.7 M (-5.83 %) |
Dec 24 2009 | CRXX | EPIRUS Biopharmace ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 0.80 | 776,899 | 621,519 | 9,231,972 | 10 M to 9.2 M (-7.76 %) |
Nov 20 2009 | AVGN | AVIGEN INC \DE | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 1.50 | 626 | 939 | 7,837,189 | 7.8 M to 7.8 M (-0.01 %) |